These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960 [TBL] [Abstract][Full Text] [Related]
25. The "STEP-wise" future of adenovirus-based HIV vaccines. Patterson LJ Curr Med Chem; 2011; 18(26):3981-6. PubMed ID: 21824093 [TBL] [Abstract][Full Text] [Related]
26. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Seaman MS; Leblanc DF; Grandpre LE; Bartman MT; Montefiori DC; Letvin NL; Mascola JR Virology; 2007 Oct; 367(1):175-86. PubMed ID: 17599382 [TBL] [Abstract][Full Text] [Related]
27. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. Hopkins R; Bridgeman A; Bourne C; Mbewe-Mvula A; Sadoff JC; Both GW; Joseph J; Fulkerson J; Hanke T Eur J Immunol; 2011 Dec; 41(12):3542-52. PubMed ID: 21932450 [TBL] [Abstract][Full Text] [Related]
28. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Rosario M; Bridgeman A; Quakkelaar ED; Quigley MF; Hill BJ; Knudsen ML; Ammendola V; Ljungberg K; Borthwick N; Im EJ; McMichael AJ; Drijfhout JW; Greenaway HY; Venturi V; Douek DC; Colloca S; Liljeström P; Nicosia A; Price DA; Melief CJ; Hanke T Eur J Immunol; 2010 Jul; 40(7):1973-84. PubMed ID: 20468055 [TBL] [Abstract][Full Text] [Related]
29. Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors. Virnik K; Nesti E; Dail C; Hockenbury M; Ni Y; Felber BK; Schief WR; Berkower I Vaccine; 2017 May; 35(24):3272-3278. PubMed ID: 28483193 [TBL] [Abstract][Full Text] [Related]
30. Vaccination with CTL epitopes that escape: an alternative approach to HIV vaccine development? O'Connor D; Allen T; Watkins DI Immunol Lett; 2001 Nov; 79(1-2):77-84. PubMed ID: 11595292 [TBL] [Abstract][Full Text] [Related]
31. Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques. Patterson LJ; Beal J; Demberg T; Florese RH; Malkevich N; Venzon D; Aldrich K; Richardson E; Kalyanaraman VS; Kalisz I; Lee EM; Montefiori DC; Robey FA; Robert-Guroff M Virology; 2008 May; 374(2):322-37. PubMed ID: 18252262 [TBL] [Abstract][Full Text] [Related]
32. Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene. Casimiro DR; Tang A; Perry HC; Long RS; Chen M; Heidecker GJ; Davies ME; Freed DC; Persaud NV; Dubey S; Smith JG; Havlir D; Richman D; Chastain MA; Simon AJ; Fu TM; Emini EA; Shiver JW J Virol; 2002 Jan; 76(1):185-94. PubMed ID: 11739684 [TBL] [Abstract][Full Text] [Related]
34. A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine. Hel Z; Johnson JM; Tryniszewska E; Tsai WP; Harrod R; Fullen J; Tartaglia J; Franchini G Vaccine; 2002 Aug; 20(25-26):3171-86. PubMed ID: 12163269 [TBL] [Abstract][Full Text] [Related]
35. Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost. Virnik K; Nesti E; Dail C; Scanlan A; Medvedev A; Vassell R; McGuire AT; Stamatatos L; Berkower I Vaccine; 2018 Aug; 36(34):5166-5172. PubMed ID: 30037665 [TBL] [Abstract][Full Text] [Related]
36. HIV Env conserved element DNA vaccine alters immunodominance in macaques. Hu X; Valentin A; Rosati M; Manocheewa S; Alicea C; Chowdhury B; Bear J; Broderick KE; Sardesai NY; Gall SL; Mullins JI; Pavlakis GN; Felber BK Hum Vaccin Immunother; 2017 Dec; 13(12):2859-2871. PubMed ID: 28678607 [TBL] [Abstract][Full Text] [Related]
37. Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins. Laube LS; Burrascano M; Dejesus CE; Howard BD; Johnson MA; Lee WT; Lynn AE; Peters G; Ronlov GS; Townsend KS Hum Gene Ther; 1994 Jul; 5(7):853-62. PubMed ID: 7981310 [TBL] [Abstract][Full Text] [Related]
38. Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses. Richardson MW; Mirchandani J; Silvera P; Régulier EG; Capini C; Bojczuk PM; Hu J; Gracely EJ; Boyer JD; Khalili K; Zagury JF; Lewis MG; Rappaport J DNA Cell Biol; 2002 Sep; 21(9):637-51. PubMed ID: 12396606 [TBL] [Abstract][Full Text] [Related]
39. Vaccines and vaccine strategies against HIV. Stratov I; DeRose R; Purcell DF; Kent SJ Curr Drug Targets; 2004 Jan; 5(1):71-88. PubMed ID: 14738219 [TBL] [Abstract][Full Text] [Related]
40. Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost. Vinner L; Wee EG; Patel S; Corbet S; Gao GP; Nielsen C; Wilson JM; Ertl HCJ; Hanke T; Fomsgaard A J Gen Virol; 2003 Jan; 84(Pt 1):203-213. PubMed ID: 12533717 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]